Ovarian cancer response to immunotherapy is limited; however, the evaluation of
sensitive/resistant target treatment subpopulations based on stratification by tumor …

Dendritic-cells (DCs) have received considerable attention as potential targets for the
development of anticancer vaccines. DC-based anticancer vaccination relies on patient …

Dendritic cells (DCs) are a heterogeneous group of antigen-presenting innate immune cells
that regulate adaptive immunity, including against cancer. Therefore, understanding the …

Cancer incidence and mortality rates are increasing annually. Treatment with surgery,
chemotherapy and radiation therapy (RT) is unsatisfactory because many patients have …

Myeloid-derived suppressor cells (MDSCs) are heterogeneous and poorly mature cells of
innate immunity that their population is increased substantially in cancer patients. MDSCs …

Tumors have special features that make them distinct from their normal counterparts.
Immature cells in a tumor mass and their critical contributions to the tumorigenesis will open …

Ovarian cancer (OC) is one of the most lethal malignant gynecologic tumors, characterized
by an uncertain presentation and poor outcomes. With or without neoadjuvant …

Background Most patients with epithelial ovarian cancer (EOC) relapse despite primary
debulking surgery and chemotherapy (CT). Autologous dendritic cell immunotherapy …

Simple Summary With an overall 5-year survival of only 20% for advanced-stage ovarian
cancer patients, enduring and effective therapies are a highly unmet clinical need. Current …

Cancer vaccines hold considerable promise for the immunotherapy of solid tumors.
Nanomedicine offers several strategies for enhancing vaccine effectiveness. In particular …